Ameriprise
SION

Ameriprise’s Sionna Therapeutics SION Stock Holding History

Ameriprise’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.29M Sell
81,974
-19,669
-19% -$751K ﹤0.01% 2701
2025
Q4 		$4.18M Sell
101,643
-51,508
-34% -$1.95M ﹤0.01% 2563
2025
Q3 		$4.5M Sell
153,151
-83,662
-35% -$1.82M ﹤0.01% 2518
2025
Q2 		$4.11M Buy
236,813
+27,547
+13% +$361K ﹤0.01% 2508
2025
Q1 		$2.19M Buy
+209,266
New +$3.42M ﹤0.01% 2848

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ameriprise's SION Position: Q1 2026 in Review

Ameriprise reduced its Sionna Therapeutics (SION) stake by 19% in Q1 2026, selling an estimated $751K and leaving 81,974 shares worth $3.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2701.

Ameriprise first reported a position in SION in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.5M in Q3 2025. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • Ameriprise held 81,974 shares of Sionna Therapeutics worth $3.29M as of Q1 2026.
  • Ameriprise sold 19,669 Sionna Therapeutics shares in Q1 2026, an estimated $751K.
  • Sionna Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2701 holding.
  • Ameriprise first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Ameriprise's Sionna Therapeutics position peaked at $4.5M in Q3 2025.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.